ICH E6 is the international standard that governs how clinical trials involving human participants must be designed, conducted, and reported. Known formally as the ICH Guideline for Good Clinical Practice (GCP), it sets the ethical and scientific rules that researchers, pharmaceutical companies, and oversight committees must follow when testing new drugs or medical treatments on people. Its two core goals are protecting the rights, safety, and well-being of trial participants and ensuring that clinical trial data are credible and reliable.
The guideline was created by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), a body that brings together regulatory agencies and the pharmaceutical industry. The original purpose was to create a unified standard for the European Union, Japan, and the United States so that clinical data generated in one region would be accepted by regulators in others, avoiding the need to repeat expensive trials.
What ICH E6 Actually Covers
At its foundation, ICH E6 lays out a set of core principles rooted in the Declaration of Helsinki, the landmark document on ethical research involving humans. These principles touch nearly every aspect of a clinical trial. Among the most important: informed consent is a non-negotiable part of ethical research, every trial must be reviewed by an independent ethics committee, trials must be scientifically sound and based on current knowledge, and only qualified individuals should design and conduct them.
The guideline also emphasizes proportionality. The safeguards and oversight built into a trial should match the level of risk to participants and the importance of the data being collected. A low-risk trial comparing two established treatments doesn’t need the same layer of monitoring as a first-in-human study of a novel drug. Investigational products used in trials must be manufactured, stored, shipped, and handled according to strict quality standards. And every role and responsibility in a trial, from the sponsor funding it to the nurse collecting blood samples, should be clearly documented.
How It Protects People in Clinical Trials
The informed consent process is one of the most detailed sections of ICH E6. Before anyone enrolls in a trial, they must receive specific information in clear language. This includes the purpose of the trial, what treatments or procedures are involved, which aspects are experimental, the foreseeable risks, and the reasonably expected benefits. Participants must also be told about alternative treatments available outside the trial.
Beyond the medical details, participants must be informed of several practical matters: how long their participation will last, roughly how many other people are in the trial, whether they’ll be compensated, what happens if they’re injured during the study, and what expenses they might face. The guideline makes clear that participation is always voluntary. A person can refuse to join or withdraw at any time without penalty. Their medical records remain confidential, though monitors, auditors, ethics committees, and regulators are granted access to verify that the trial is being run properly.
If new findings emerge during the trial that might affect someone’s willingness to continue, the research team is required to share that information with them.
The Role of Ethics Committees
Every clinical trial under ICH E6 must be reviewed and approved by an institutional review board (IRB) or independent ethics committee (IEC) before it begins. These bodies exist specifically to safeguard participants. They review all the essential trial documents, including the study protocol, the informed consent form, and information about the investigational product, to assess whether the trial is ethically acceptable and scientifically justified.
The guideline requires these committees to have written procedures governing how they operate and to maintain records of their decisions. Their oversight doesn’t end at approval. They continue monitoring the trial throughout its duration, reviewing any amendments, safety reports, or protocol changes that arise.
What Investigators Are Expected to Do
The principal investigator, typically a physician, carries ultimate responsibility for the conduct of a trial at their site. Even when tasks are delegated to nurses, coordinators, or pharmacists, the investigator is accountable for making sure everything is done correctly. This includes understanding the study protocol in detail, supervising the handling and storage of investigational drugs, and being available to the research team for questions and decisions.
Investigators must document all adverse events that occur during a trial and review them regularly with their team, since a side effect might require a dose change or even stopping a participant’s treatment. When something goes wrong procedurally, such as a missed visit or a blood sample drawn at the wrong time, the site must log the deviation and develop a corrective action plan describing how similar mistakes will be prevented going forward.
Versions of the Guideline
ICH E6 has gone through several revisions. The version most widely implemented for years was E6(R2), which added an emphasis on risk-based monitoring and quality management. Rather than requiring monitors to verify every single data point at every site, R2 allowed sponsors to focus their oversight on the data and processes most critical to participant safety and data integrity.
The latest version, E6(R3), was endorsed by the ICH Assembly in January 2025 and published by the FDA in September 2025. It represents a significant modernization. Key updates include greater flexibility to support modern trial designs (such as decentralized trials where participants engage remotely), support for new data sources and technologies, stronger emphasis on quality by design and risk-based quality management, and clearer definitions of sponsor and investigator responsibilities. The guideline now promotes proportionality and critical thinking throughout the entire trial lifecycle rather than relying on rigid, one-size-fits-all checklists.
Where ICH E6 Applies
ICH E6 is adopted as a regulatory standard by agencies across the world. The FDA in the United States, the European Medicines Agency, Japan’s regulatory authority, and Health Canada all require compliance with ICH GCP for clinical trials submitted in support of drug approvals. Health Canada, for example, has announced it will implement E6(R3) effective April 1, 2026. Many countries beyond the original ICH members also follow the guideline, making it the closest thing to a universal rulebook for clinical research.
For pharmaceutical companies and research organizations, compliance with ICH E6 isn’t optional. Regulatory agencies can reject trial data, halt ongoing studies, or take enforcement action against sites or sponsors that fail to meet GCP standards. For the millions of people who volunteer for clinical trials each year, it’s the primary framework ensuring that their participation is treated with the seriousness and ethical rigor it deserves.